Bellicum Pharmaceuticals is halting the Phase I/II trials for the only two candidates in its pipeline after reporting a serious adverse event — and is now evaluating “strategic alternatives” for the company after a rocky few years.
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally.
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of September 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.
Bellicum Reports Q2 2022 Rusult and Provides Operational Update
HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...